Zevra Therapeutics (ZVRA) has shared an update.
Zevra Therapeutics has announced an upcoming FDA review with the Genetic Metabolic Diseases Advisory Committee to discuss the New Drug Application for arimoclomol, a potential treatment for Niemann-Pick disease type C. Slated for August 2, 2024, this key meeting precedes the drug’s PDUFA action date on September 21, 2024. The company’s forward-looking statements, while based on current plans, highlight that actual results may vary due to various risks and uncertainties.
For an in-depth examination of ZVRA stock, go to TipRanks’ Stock Analysis page.
